Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma.
Level V
Where this comes from
- Record sourced from PubMed, PMID 36758558.
- Also identified by DOI 10.1097/RLU.0000000000004598.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High-specific-activity 131 I-MIBG (Azedra) is the only Food and Drug Administration-approved therapy for metastatic pheochromocytomas and paragangliomas, which are rare neuroendocrine tumors with limited treatment options. Based on our experience, we proposed here functional imaging-based tumor response criteria for these patient cohorts. Each response category was illustrated with typical sample cases, and clinical correlation was provided.
Medical subject headings
- Pheochromocytoma
- Paraganglioma
- Adrenal Gland Neoplasms
- Neuroendocrine Tumors
- Peripheral Nervous System Neoplasms
- Brain Neoplasms
- Neoplasms, Second Primary